This is a multicenter, randomized, controlled, phase II study assessing the efficacy and safety of Almonertinib versus Paclitaxel Plus Carboplatin as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic Pulmonary Adenosquamous Carcinoma. Eligible patients will be randomized to receive either Almonertinib (110mg, po, once daily) or paclitaxel (175mg/m2, iv) plus carboplatin (AUC=5, iv) in a 1:1 ratio.
This is a multicenter, randomized, controlled, phase II study.